Skip to main content
. 2016 Oct;7(5):804–818. doi: 10.21037/jgo.2016.08.05

Table 1. United States Food and Drug Administration approval of agents for NETs within the last 10 years.

Date of FDA approval Drug Indication
05/06/2011 Everolimus Unresectable, locally advanced or metastatic, progressive pancreatic NET
05/20/2011 Sunitinib Unresectable, locally advanced or metastatic, progressive pancreatic NET
12/16/2014 Lanreotide Unresectable, well or moderately differentiated, locally advanced or metastatic GEP-NETs to improve progression-free survival
02/26/2016 Everolimus Unresectable, well differentiated, locally advanced or metastatic, non-functional, progressive gastrointestinal or lung NET

FDA, Food and Drug Administration; GEP, gastroenteropancreatic; NETs, neuroendocrine tumors.